Hematologic Oncology

Overall survival was the sole US primary end point of the phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab and was not met.

Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.

Johannes Schetelig, MD, MSc, discusses data for anti–T-lymphocyte globulin vs post-transplant cyclophosphamide for GVHD prophylaxis in hematologic malignancies.

Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.

Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

Ruxolitinib plus extracorporeal photopheresis drove responses in steroid-refractory or -dependent chronic graft-vs-host disease.

Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for untreated classical Hodgkin lymphoma.

Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress

The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.

The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.

The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.

Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.

Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.

Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine and cedazuridine plus venetoclax in acute myeloid leukemia.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.

Julia Scarisbrick reviews real-world data showing mogamulizumab eased itch, pain, flaking, sleep, and fatigue in MF and Sézary syndrome as early as 4 weeks.

Christiane Querfeld, MD, PhD, discusses why early symptom relief drives adherence in mycosis fungoides and Sézary syndrome, and reframing MAR as an immune flare helps patients stay the course.

Christiane Querfeld, MD, PhD, discusses how targeted sequencing data show Sézary syndrome responds to mogamulizumab better than mycosis fungoides.

Jan P. Nicolay, MD, PhD, explains how early single-cell data suggest mogamulizumab resistance switches on anti-apoptotic survival proteins.